Skip to main content

Table 3 Univariate and multivaritate analyses of overall survival and disease-free survival of patients with ESCC

From: Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma

  Overall survival P Disease-free survival P
HR (95% CI)   HR (95% CI)  
Univariate analysis
 Gender (Male vs. female) 0.290 (0.040–2.124) 0.223 0.345 (0.047–2.517) 0.294
 Age (y) (< 60 vs. ≥60) 0.786 (0.401–1.507) 0.469 0755 (0.401–1.423) 0.385
 Alcohol (Light vs. Heavy) 1.711 (0.873–3.354) 0.118 1.825 (0.940–3.543) 0.075
 Smoking (Light vs. Heavy) 1.261 (0.664–2.395) 0.479 1.239 (0.664–2.311) 0.501
 Stage (I/II vs. III/IV) 1.421 (0.744–2.714) 0.288 1.559 (0.830–2.927) 0.167
 Differentiation (WD vs. MD/PD) 1.425 (0.641–3.170) 0.385 1.418 (0.667–3.018) 0.364
 Location (upper/middle vs. lower) 1.139 (0.560–2.316) 0.720 1.305 (0.658–2.591) 0.446
 Adjuvant therapy 1.437 (0.698–2.960) 0.325 1.814 (0.916–3.593) 0.088
 Resection margin (R0 vs. R1) 1.050 (0.370–2.976) 0.927 1.286 (0.454–3.638) 0.636
 Vascular invasion 1.992 (1.009–3.934) 0.047 1.932 (0.992–3.765) 0.053
 Lymphatic invasion 1.856 (0.944–3.648) 0.073 1.905 (0.989–3.671) 0.054
 Perineural invasion 1.951 (0.934–4.073) 0.075 2.083 (0.998–4.345) 0.051
 Dysplasia 0.574 (0.296–1.115) 0.101 0.478 (0.716–3.064) 0.031
 PD-L1 (negative vs. positive) 0.084 (0.256–1.090) 0.078 0.458 (0.222–0.944) 0.034
 MSI/dMMR 1.667 (0.780–3.564) 0.187 1.804 (0.879–3.704) 0.108
PIK3CA mutation 1.876 (0.777–4.530) 0.162 1.818 (0.756–4.373) 0.182
Multivariate analysis
 Vascular invasion 1.818 (0.824–4.009) 0.139 1.622 (0.726–3.623) 0.239
 Lymphatic invasion 1.557 (0.707–3.429) 0.271 1.725 (0.747–3.983) 0.202
 Perineural invasion 1.435(0.646–3.188) 0.376 1.069(0.449–2.544) 0.880
 PD-L1 (negative vs. positive) 0.416 (0.196–0.885) 0.023 0.379 (0.174–0.824) 0.014
 Alcohol (Light vs. Heavy) 1.792(0.868–3.701) 0.115
 Adjuvant therapy 2.009(0.896–4.504) 0.090
 Dysplasia 0.701(0.341–1.444) 0.336
  1. ESCC esophageal squamous cell carcinoma, HR hazard ratio, CI 95% confidence interval, WD well-differentiation, MD moderately-differentiation, PD poorly-differentiation, PD-L1 programmed death ligand-1, MSI microsatellite instability, dMMR deficient mismatch repair